Edwards Lifesciences has just launched a new device designed to eliminate an external cross clamp in minimal incision valve surgery (MIVS) cases. The company says the ThruPort IntraClude Intra-Aortic Occlusion Device provides surgeons with “excellent visualization and a virtually bloodless, unobstructed operative field, enabling mitral valve repair or replacement through the smallest possible incision.”
The device is delivered via the femoral artery approach and occludes the ascending aorta between 2.0 cm to 4.0 cm in width by an inflatable balloon.
Features of the device according to Edwards:
It features a 9 French shaft that is delivered via the femoral artery and occludes the ascending aorta, enabling the use of fewer products within the principal incision site to maximize visualization of the surgical field and cardiac structures.
The device also provides for multiple functions in a single device, delivering antegrade cardioplegia solution to stop the heart and protect it during surgery, venting the aortic root to facilitate a bloodless surgical field and monitoring aortic root pressure to verify the occlusion of the ascending aorta throughout the surgery. IntraClude also maximizes perfusion flow rates to provide low perfusion pressures and protect the patient while on cardiopulmonary bypass.
- 9 Fr, triple lumen catheter
– Central lumen provides for antegrade cardioplegia delivery, aortic root venting
and guidewire passage
– Blue lumen enables balloon inflation/deflation
– Red lumen enables reliable aortic root pressure monitoring
- 100 cm in length with an elastomeric balloon at the tip
– Balloon expands to occlude a range of aorta sizes (2.0 cm to 4.0 cm)
- Packaging also includes:
– 200 cm 0.038” J-tip guidewire
– 35 mL syringe
– Red and blue pressure lines
Product page: IntraClude Device…